The Dream Team Biopsy Study: Guided Biopsies for Men
The Dream Team Biopsy Study: Guided Biopsies for Men with Metastatic Castration Resistant Prostate Cancer
Technical Title: Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms of Resistance
Disease Type: Metastatic, castration-resistant prostate cancer
The purpose of this study is to better understand how cancer treatment may affect cancer cells. The research will involve genetic, molecular, cellular, and immunologic experiments using blood and tumor specimens. It is hoped that the information gained from these studies will lead to a greater understanding of castrate-resistant prostate cancer and potentially, improvements in cancer treatment.
Research Procedures (not a complete list):
If you take part in this study, the researcher(s) will ask you to undergo the following tests and procedures during the study:
- Research tumor biopsy – the biopsy will take approximately 45 minutes, and you will be monitored while you recover for 2 hours after the biopsy. If your tumor lends itself to additional cores being taken, the doctor may remove up to four additional core samples during the biopsy. These extra samples will be used to develop “patient-derived tumor models” for ongoing and future research. Specifically, cancer cells will be grown outside of the body to study tumor biology and response to therapies, with a goal of developing future cancer clinical trials for patients.
- Research blood draw – 3 months after your biopsy, additional blood will be collected for research testing.
- Collection of tissue from a past procedure (optional)
- Review of PSA testing and imaging that you receive as part of your routine care
At the time that your cancer progresses, you withdraw from the study, or the study is closed, you will be asked to return to the clinic for the following procedures. The visit will take approximately 1 hour.
- Research blood draw
- PSA testing that you receive as part of your routine care
- Optional research tumor biopsy: A second tumor biopsy may be considered at the time your cancer progresses. The tissue from this biopsy will help us understand changes in your cancer’s characteristics that occur while you are receiving treatment
Eligibility Criteria (not a complete list):
- Diagnosis of metastatic, castration-resistant prostate cancer
- Prostate cancer progressed after being treated with abiraterone, enzalutamide, or ARN509-based therapy, or after being treated on specific clinical trials (the study team can clarify these trials for you)
- Prior chemotherapy treatment for your prostate cancer
For More Detailed Information, Contact:
- Robert Reiter, MD, Principal Investigator
- Colleen Mathis, Study Coordinator, 310-794-2731